Terms: = Kidney tumors AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
734 results:
1. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/pd-l1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
2. Association between pd-l1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract] [Full Text] [Related]
3. GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.
Huang S; Liu J; Hu J; Hou Y; Hu M; Zhang B; Luo H; Fu S; Chen Y; Liu X; Chen Z; Wang L
J Cell Mol Med; 2024 Apr; 28(8):e18290. PubMed ID: 38588015
[TBL] [Abstract] [Full Text] [Related]
4. Bispecific fibrous glue synergistically boosts vascular normalization and antitumor immunity for advanced renal carcinoma therapy.
Wu XH; Wang JQ; Wang MD; Xiao T; Wang Y; Niu JY; Wang L; Hou DY; Fu B; Liu Z; Wang H; Xu W
Biomaterials; 2024 Jul; 308():122550. PubMed ID: 38581762
[TBL] [Abstract] [Full Text] [Related]
5. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
6. Nicotinamide phosphoribosyltransferase modulates pd-l1 in bladder cancer and enhances immunotherapeutic sensitivity.
Chen KC; Dhar T; Chen CR; Chen EC; Peng CC
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167106. PubMed ID: 38428685
[TBL] [Abstract] [Full Text] [Related]
7. Association of Androgen Receptor and pd-l1 Expression in Upper Urinary Tract Urothelial Carcinoma.
Okuda Y; Kato T; Fujita K; Fushimi H; Miyamoto H; Netto GJ; Nonomura N
Cancer Genomics Proteomics; 2024; 21(2):137-143. PubMed ID: 38423597
[TBL] [Abstract] [Full Text] [Related]
8. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract] [Full Text] [Related]
9. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract] [Full Text] [Related]
10. Noninvasive Evaluation of Tumoral pd-l1 Using a Novel
Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
[TBL] [Abstract] [Full Text] [Related]
11. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
Choueiri TK; Donahue AC; Braun DA; Rini BI; Powles T; Haanen JBAG; Larkin J; Mu XJ; Pu J; Teresi RE; di Pietro A; Robbins PB; Motzer RJ
Cancer Discov; 2024 Mar; 14(3):406-423. PubMed ID: 38385846
[TBL] [Abstract] [Full Text] [Related]
12. Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.
Tian J; Luo J; Zeng X; Ke C; Wang Y; Liu Z; Li L; Zhang Y; Hu Z; Yang C
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38355278
[TBL] [Abstract] [Full Text] [Related]
13. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract] [Full Text] [Related]
14. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
15. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
16. Experience with pembrolizumab in a renal transplant patient with advanced lung cancer: a case report and review.
Fernández Madrigal L; García Samblásand V; Sánchez Escudero L
Anticancer Drugs; 2024 Apr; 35(4):377-382. PubMed ID: 38271682
[TBL] [Abstract] [Full Text] [Related]
17. Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity
Ghosh S; Garige M; Haggerty PR; Norris A; Chou CK; Wu WW; Shen RF; Sourbier C
Cell Cycle; 2024 Jan; 23(1):43-55. PubMed ID: 38263737
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of the immunological markers BTLA, TIM-3, and pd-l1 at the invasion front and tumor center in clear cell renal cell carcinoma.
Stühler V; Alemi B; Rausch S; Stenzl A; Schwab M; Schaeffeler E; Bedke J
World J Urol; 2024 Jan; 42(1):53. PubMed ID: 38244072
[TBL] [Abstract] [Full Text] [Related]
19. Pathological findings directing immunotherapy in renal cell carcinomas.
Gökalp Satıcı FE; Karabulut YY
Immunotherapy; 2024 Mar; 16(4):199-204. PubMed ID: 38214137
[TBL] [Abstract] [Full Text] [Related]
20. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract] [Full Text] [Related]
[Next]
